Lyell Immunopharma ( (LYEL) ) just unveiled an announcement.
Lyell Immunopharma is set to acquire ImmPACT Bio to bolster its pipeline with advanced CAR T-cell therapies, focusing on IMPT-314, a promising dual-targeting treatment for B-cell lymphoma. The acquisition aims to enhance Lyell’s clinical-stage offerings and drive innovation in cancer treatments. With the deal valued at $30 million in cash and shares, Lyell plans to prioritize next-generation therapies, discontinuing some existing programs to concentrate resources on the most differentiated candidates, with operations funded through 2027.
Learn more about LYEL stock on TipRanks’ Stock Analysis page.
